礼来:从被拉下神坛的诺和诺德手中抢夺市场份额(纽交所:LLY)

· seekingalpha.com

在竞争加剧的背景下,礼来(LLY)在全球肥胖药物市场中领先于诺和诺德。

Obesity drug investors in Eli Lilly ( LLY ) are riding high and I think they deserve it. After the stock bottomed out in May this year, it hasn't looked back

J...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI